Users Online: 510
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

REVIEW ARTICLE

Management of relapsed-refractory diffuse large B cell lymphoma

Raut Lalit S, Chakrabarti Prantar P

Year : 2014| Volume: 3| Issue : 1 | Page no: 66-70

   This article has been cited by
 
1 Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
Xu-Wen Guan,Hua-Qing Wang,Wei-Wei Ban,Zhi Chang,Hai-Zhu Chen,Li Jia,Feng-Ting Liu
Cell Death & Disease. 2020; 11(1)
[Pubmed]  [Google Scholar] [DOI]
2 Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
Gary H. Lyman,Andy Nguyen,Sophie Snyder,Matthew Gitlin,Karen C. Chung
JAMA Network Open. 2020; 3(4): e202072
[Pubmed]  [Google Scholar] [DOI]
3 The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy
Joseph Tkacz,Jacob Garcia,Mathew Gitlin,Donna McMorrow,Sophie Snyder,Machaon Bonafede,Karen C. Chung,Richard T. Maziarz
Leukemia & Lymphoma. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
4 Assessment of epigenetic mechanisms and DNA double-strand break repair using laser micro-irradiation technique developed for hematological cells
Danielle P. Johnson,Gabriella S. Spitz-Becker,Korak Chakraborti,Srividya Bhaskara
EBioMedicine. 2019;
[Pubmed]  [Google Scholar] [DOI]
5 Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience
Daria Gaut,Tahmineh Romero,David Oveisi,Grant Howell,Gary Schiller
Hematological Oncology. 2019;
[Pubmed]  [Google Scholar] [DOI]
6 Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen
Hussein M Khaled,Thoraya M Abdelhamid,Fouad M Abu-Taleb,Niveen M El-Hifnawi,Ahmad B Waley
Future Science OA. 2019; : FSO414
[Pubmed]  [Google Scholar] [DOI]
7 Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma
Ling Wang,Hung Lam,Yaping Shou,Aaron Galaznik
Oncotarget. 2019; 10(35): 3285
[Pubmed]  [Google Scholar] [DOI]
8 Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma
Qian Huang,Feifei Liu,Jianzhen Shen
Personalized Medicine. 2019;
[Pubmed]  [Google Scholar] [DOI]
9 Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma
Ane Larrabeiti-Etxebarria,Maria Lopez-Santillan,Borja Santos-Zorrozua,Elixabet Lopez-Lopez,Africa Garcia-Orad
Cancers. 2019; 11(2): 144
[Pubmed]  [Google Scholar] [DOI]
10 Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice
Alessandro Broccoli,Beatrice Casadei,Annalisa Chiappella,Carlo Visco,Monica Tani,Nicola Cascavilla,Annarita Conconi,Monica Balzarotti,Maria Christina Cox,Dario Marino,Maria Cecilia Goldaniga,Roberto Marasca,Cristina Tecchio,Caterina Patti,Gerardo Musuraca,Liliana Devizzi,Federico Monaco,Alessandra Romano,Angelo Fama,Michelle Zancanella,Rossella Paolini,Luigi Rigacci,Claudia Castellino,Francesco Gaudio,Lisa Argnani,Pier Luigi Zinzani
The Oncologist. 2019; 24(9): 1246
[Pubmed]  [Google Scholar] [DOI]
11 The fear of lymphadenopathy: A cautionary case of sarcoidosis masquerading as recurrent diffuse large b-cell lymphoma (DLBCL)
Peter D. Whooley,Russell K. Dorer,David M. Aboulafia
Leukemia Research Reports. 2018; 9: 48
[Pubmed]  [Google Scholar] [DOI]
12 Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma
Lucia Baratto,Guido A. Davidzon,Mateen Moghbel,Negin Hatami,Andrei Iagaru,Erik S. Mittra
Clinical Nuclear Medicine. 2018; 43(1): 1
[Pubmed]  [Google Scholar] [DOI]
13 Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments
Rachel Salzman,Francesca Cook,Timothy Hunt,Harry L. Malech,Philip Reilly,Betsy Foss-Campbell,David Barrett
Molecular Therapy. 2018;
[Pubmed]  [Google Scholar] [DOI]
14 Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group
Reena Nair,Abhishek Kakroo,Ajay Bapna,Ajay Gogia,Amish Vora,Anand Pathak,Anu Korula,Anupam Chakrapani,Dinesh Doval,Gaurav Prakash,Ghanashyam Biswas,Hari Menon,Maitreyee Bhattacharya,Mammen Chandy,Mayur Parihar,M. Vamshi Krishna,Neeraj Arora,Nikhil Gadhyalpatil,Pankaj Malhotra,Prasad Narayanan,Rekha Nair,Rimpa Basu,Sandip Shah,Saurabh Bhave,Shailesh Bondarde,Shilpa Bhartiya,Soniya Nityanand,Sumeet Gujral,T. V. S. Tilak,Vivek Radhakrishnan
Indian Journal of Hematology and Blood Transfusion. 2018; 34(3): 398
[Pubmed]  [Google Scholar] [DOI]
15 Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma: a systematic review
Maria Lopez-Santillan,Ane Larrabeiti-Etxebarria,Javier Arzuaga-Mendez,Elixabet Lopez-Lopez,Africa Garcia-Orad
Oncotarget. 2018; 9(32): 22850
[Pubmed]  [Google Scholar] [DOI]
16 Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful
Hina J. Shah,Abhishek R. Keraliya,Jyothi P. Jagannathan,Sree Harsha Tirumani,Vikram R. Lele,Pamela J. DiPiro
Korean Journal of Radiology. 2017; 18(1): 54
[Pubmed]  [Google Scholar] [DOI]
17 Circulating CXCR5+CD4+ T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway
Zhanshan Cha,Guangfang Qian,Yan Zang,Haihui Gu,Yanyan Huang,Lishuang Zhu,Jinqi Li,Yang Liu,Xiaohua Tu,Haihan Song,Baohua Qian
Experimental Cell Research. 2017; 350(1): 154
[Pubmed]  [Google Scholar] [DOI]
18 Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?
Amit Dipak Amin,Tara L. Peters,Lingxiao Li,Soumya Sundara Rajan,Ramesh Choudhari,Soham D. Puvvada,Jonathan H. Schatz
Molecular Case Studies. 2017; 3(3): a001719
[Pubmed]  [Google Scholar] [DOI]
19 A novel anti-CD22 scFv–apoptin fusion protein induces apoptosis in malignant B-cells
Solmaz Agha Amiri,Soraya Shahhosseini,Najmeh Zarei,Dorsa Khorasanizadeh,Elahe Aminollahi,Faegheh Rezaie,Mehryar Zargari,Mohammad Azizi,Vahid Khalaj
AMB Express. 2017; 7(1)
[Pubmed]  [Google Scholar] [DOI]
20 Chimeric Antigen Receptor T-Cell Therapy for Lymphomas
Benjamin Jolley,Scot Walker
Hospital Pharmacy. 2017; 52(7): 469
[Pubmed]  [Google Scholar] [DOI]
21 PD-1 expression on the surface of peripheral blood CD4+ T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma
Wei Zhang,Jie-Fei Bai,Meng-Xuan Zuo,Xin-Xin Cao,Miao Chen,Yan Zhang,Xiao Han,Ding-Rong Zhong,Dao-Bin Zhou
Cancer Medicine. 2016; 5(11): 3077
[Pubmed]  [Google Scholar] [DOI]
22 Antitumor activity of fucoidan against diffuse large B cell lymphomain vitroandin vivo
Guang Yang,Qianqiao Zhang,Yuanyuan Kong,Bingqian Xie,Minjie Gao,Yi Tao,Hongwei Xu,Fenghuang Zhan,Bojie Dai,Jumei Shi,Xiaosong Wu
Acta Biochimica et Biophysica Sinica. 2015; 47(11): 925
[Pubmed]  [Google Scholar] [DOI]
23 A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma
Hongli Zhao,Guoxun Sun,Desheng Kong,Yujing Zhang,Wudan Shi,Mingming Zhao,Luojia Hong,Zhenkui Qiao
Medical Oncology. 2015; 32(3)
[Pubmed]  [Google Scholar] [DOI]
24 Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin’s lymphoma patients with a poor performance status or comorbidity
XUEDE LIN,XI SHI,WUCHA ZENG,MIN ZHENG,LIMING HUANG
Oncology Letters. 2014; 8(5): 2012
[Pubmed]  [Google Scholar] [DOI]

 

Read this article